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ORIGINAL ARTICLE
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Orest Abrahamovycha , Ostap Yatskevycha , Georg Waege, Olha Yelisyeyevaf and Neven Zarkovicc
aDepartment of Internal Medicine #1, Danylo Halytskyi Lviv National Medical University, Lviv, Ukraine; bDivision of Pathology, Clinical
Hospital Centre “Zagreb”, University of Zagreb School of Medicine, Zagreb, Croatia; cLaboratory for Oxidative Stress (LabOS), Institute
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ABSTRACT
Helicobacter pylori-induced oxidative stress in gastric mucosa (GM) is a milieu for the develop-
ment of chronic gastritis, duodenal peptic ulcer (DPU), gastric cancer, and a number of extragas-
tric diseases. Because our previous study revealed the accumulation of the protein adducts of
lipid peroxidation product 4-hydroxynonenal (HNE) in GM, which persists after eradication of H.
pylori, the aim of the study was to test whether Amaranth oil supplementation in addition to
standard anti-Helicobacter treatment could prevent such accumulation of HNE in GM in H. pylori-
positive DPU patients. Seventy-five patients were randomly split into two groups: group 1 –
standard treatment (n¼ 39) and group 2 – standard treatment with additional supplementation
of 1ml of concentrated oil from amaranth seeds (Amaranthus cruenthus L., n¼ 36). Clinical ana-
lysis, including endoscopy with biopsies from antrum and corpus of the stomach were performed
before and after the treatment, as was heart rate variability (HRV) recorded, as parameter of sys-
temic, extragastric pathophysiological alterations in DPU patients. Improvement of clinical, endo-
scopic and histologic manifestations, and successful ulcer healing were observed in both the
groups. Moreover, supplementation of amaranth oil in addition to standard anti-H. pylori treat-
ment significantly reduced accumulation of HNE-histidine adducts in GM and increased HRV in
DPU patients (p< .05). Therefore, standard treatments of DPU require additional therapeutic
approaches, in accordance with integrative medicine principles, aiming to reduce persistence of
oxidative stress, as was successfully done in our study by the use of amaranth oil.
Abbreviations: AO: Amaranth oil; DPU: duodenal peptic ulcer; GM: gastric mucosa; HF: high fre-
quency; HNE: 4-hydroxy-2-nonenal; H. pylori: Helicobacter pylori; HRV: heart rate variability; LF: low
frequency; OS: oxidative stress; OT: orthostatic test; pNN50: percentage of differences between
adjacent normal RR intervals exceeding 50 milliseconds; RMSSD: square root of the mean squared
differences of successive RR intervals; ROS: reactive oxygen species; SDNN: standard deviation of
normal RR intervals; TP: total power; VLF: very low frequency
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Introduction
Duodenal peptic ulcer (DPU) is one of the most com-
mon diseases of gut and its complications include life-
threatening conditions such as perforation, penetration,
and bleeding. The link between Helicobacter pylori and
DPU, as well as with chronic gastritis, gastric cancer,
and MALT-lymphoma is well established [1]. A growing
evidence shows that H. pylori may be associated with
the so-called “extra-gastric manifestations” such as insu-
lin resistance, metabolic syndrome, nonalcoholic
fatty liver disease, atherosclerosis, autoimmune, and
neurodegenerative diseases, etc. [2,3]. Recent large
cohort study demonstrated positive association of
H. pylori-positivity with body mass index, a major risk
factor of metabolic diseases, regardless socioeconomic
status and other cofounders [4], clearly indicating sub-
stantial systemic metabolic effects of H. pylori infection.
Fortunately, eradication of H. pylori was proven to be
effective treatment of chronic gastritis and peptic ulcer,
and potentially could be effective in the prevention of
gastric cancer and other diseases associated with this
microorganism [5,6].
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Helicobacter pylori is known to be able to induce
local damage to gastric epithelial cells and cause inflam-
mation in gastric mucosa (GM). This is associated with
migration of neutrophils and development of gastritis.
It is assumed that chronic gastritis with or without the
ulcer may significantly contribute to systemic effects of
H. pylori. Excessive generation of reactive oxygen spe-
cies (ROS) induced by microorganism’s virulence factor,
predominantly CagA in GM and oxidative burst caused
by activated neutrophils leads to the development of
local oxidative stress (OS) [3]. It is also possible that
local OS and low-grade inflammation caused by persist-
ence of H. pylori in human stomach are major contribu-
tors to its extragastric manifestations [7,8]. Released
into circulation tissue degradation products as well as
multiple regulatory molecules may exert significant sys-
temic effects. However, intensity of inflammation should
be strong enough to overcome detoxifying function of
liver, which serves as a natural “filter” for all kinds of
substances coming from the gut [8,9].
Oxidative stress is often associated with increased
accumulation of lipid peroxidation products, among
which 4-hydroxy-2-nonenal (HNE) is one of the most
prominent [10]. HNE is considered to be a bioactive
marker of pathological processes and a “second
messenger” of ROS [11]. Since HNE is highly reactive, it
is difficult to detect free HNE in the organism while it
often covalently binds to proteins thus producing con-
jugates mainly with cysteine, histidine, and lysine resi-
dues [12], while the HNE–protein adducts can be
detected by immunohistochemistry [12] and ELISA [13].
These assays still remain a state of the art of the HNE
detection in biological samples and are greatly contri-
buting to modern understanding of the role of HNE as
biomarker of OS [14].
As we previously demonstrated, H. pylori causes
accumulation of the histidine adducts of HNE in GM of
DPU patients. At the same time some degree of HNE
accumulation in GM, but significantly less than in
patients, was also observed in some of apparently
healthy H. pylori-negative and positive volunteers that
also participated in the study [15]. However, eradication
of H. pylori did not cause significant reduction of HNE
accumulation, 4 weeks after eradication revealing per-
sistence of OS in GM after treatment [16]. This is also in
consistence with the evidence from randomised con-
trolled studies that eradication of H. pylori does not
reduce short-term risk of gastric cancer, while reduction
of its risk is gained only after 8–10 years after eradica-
tion, while some show even the lack of significant
effects of H. pylori eradication [5].
It remains unknown whether only the presence of
H. pylori is sufficient for causing systemic effects, or
active inflammatory process is required for that [17].
In this regard, the study focused on the determin-
ation of inflammatory parameters, HNE-water soluble
end-metabolite and 8-iso-prostaglandin F2-a as meas-
ures of OS in apparently healthy H. pylori-negative
and positive sedentary subjects did not reveal signifi-
cant differences [18]. However, the changes were
observed when heart rate variability (HRV) in these
subjects was analysed [8]. Decreased HRV, despite
the lack of clear evidence of direct link, was long
associated with OS-related diseases [19,20]. Indirect
evidence that the interventions aimed to reduce OS
could lead to improvement of HRV also support this
observation [16,21]. This is particularly important,
since modulation of autonomic control substantially
influences microcirculation, which is critical for nor-
mal gastric mucosa function. Besides, psychological
stress is additional major risk factor and can serve as
a trigger for DPU development in subjects with the
presence of other risk factors, for example H. pylori
[22], hence, the HRV is a “gold standard” for nonin-
vasive evaluation of degree of stress and autonomic
control of internal organs [23].
Since recently possible links between autonomic
regulation and redox signalling are attracting attention
of a growing number of researchers. The directions of
these studies include anti-inflammatory effects of cho-
linergic (parasympathetic) signalling [24,25], interac-
tions of adrenergic pathways with H2O2-mediated
insulin signalling [26] and thermogenesis in adipose
tissue [27]. It was reported recently that selective Nrf2
deletion in the rostral ventrolateral medulla evokes
hypertension and “sympathoexcitation” in mice point-
ing out to close relationships of autonomic regulation
and redox balance [28].
There are many interventions aimed to reduce OS
manifestations in experimental and clinical setups.
Principal approaches include integrative medicine
approaches including pharmacological treatments, sup-
plementation diet by nutraceuticals or even nutritional
deprivation (caloric restriction or intermittent fasting),
physiotherapy, and exercise [29]. It turned out that, ini-
tially considered as “antioxidant”, some interventions
were shown to be in fact prooxidant; however, their
positive effects were achieved by the stimulation of
redox signalling and activation of “protective” redox
sensitive transcription factors such as Nrf2 or FOXO
[30], which stimulate the expression of antioxidant
enzymes (thus having hormetic effects). Among other
popular, natural products used, the amaranth oil (AO)
has a unique composition and is long believed to
have beneficial health effects. A number of studies
performed on animal models as well as some human
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studies demonstrated a great potential of AO in
modulation of OS in different conditions including
high-performance sports [21], diabetes, cancer, etc. In
addition, the potential of AO to restore reduced HRV
was also demonstrated. The information available in
the literature on chemical composition of Amaranth
grains including lipid fraction was recently reviewed
[31]. Potentially active substances, including carote-
noids, tocopherols and tocotrienols, squalene, and poly-
unsaturated fatty acids [32] present in significant
concentrations in AO are capable to modulate redox
signalling, may be responsible for these effects; how-
ever, the effects of other substances present at lower
concentrations cannot be excluded as well [31].
Since OS is a major problem in DPU and there is
no evidence of reduction of HNE–histidine adducts in
GM after successful H. pylori eradication, it may be
assumed that supplementation of AO may have bene-
ficial effect on gastric mucosa when administered
orally. This is consistent with the integrative medicine
approaches to treat DPU by the holistic protocols
including nutraceutical or plant-based treatments [33]
as well. In this intervention study, we aimed to test
whether oral supplementation of AO in addition to
standard treatment (triple therapy) will have an
impact on the accumulation of HNE–histidine adducts
and histological parameters in GM, clinical
manifestations and HRV in patients with DPU 4 weeks
after standard treatment.
Patients, materials and methods
Study design and recruitment of patients
Study design is presented in Figure 1. All patients
underwent routine clinical examinations and laboratory
investigations according to existing protocols and
standards of treatment, after signing the informed con-
sent. Examination plan included upper gastrointestinal
endoscopy with biopsy from antrum and body of stom-
ach for histological examination (routine histology and
H. pylori determination), fast urease test, and HNE-
immunohistochemistry. H. pylori was determined in 75
patients (age 32.0 ± 0.8, 46 (61.3%) male and 29 (34.7%)
females). Endoscopy was performed before and after
the treatment as described below (day 0 and day 35).
Standard treatment was prescribed according to the
recommendations of second Maastricht consensus
(2000) and included lansoprazole 30mg, amoxicillin
1000mg, and clarithromycin 500mg twice per day for 7
days. In posteradication period patients were asked to
take one capsule of lansoprazole 30mg for 4 weeks
before sleep considering that normal time of ulcer heal-
ing is 3–4 weeks. There were two main time points: day
0 (a day before the beginning of treatment, usually a
Exclusion
Paents with gastrointesnal complaints 
screened by physician for indicaons for upper 
GI endoscopy, informed consent obtained
Upper GI 
endoscopy with 
biopsy
H. pylori tests
Not indicated
Indicated
No ulcer
Duodenal ulcer (N=105)
Gastric ulcer
Negave (N=30)
Posive (N=75)
Randomizaon
Group 2
Standard treatment with
Amaranth oil supplementaon (N=36)
Group 1
Standard treatment, no 
supplementaon (N=39)
Figure 1. Scheme of recruitment of patients in the study. It includes screening of subjects of respective age with presence of
gastrointestinal complaints typical for duodenal ulcer, absence of diseases, symptoms or signs of exclusion criteria. Subjects with
H. pylori-positive duodenal ulcers were randomised into study groups.
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day of endoscopy) and day 35 (4 weeks after comple-
tion of eradication treatment and a day of second
endoscopy). HRV was determined on these days.
All H. pylori-positive subjects were split into two
groups: group 1 was recommended standard treatment
as described above and group 2 received in addition to
standard treatment AO supplementation from day 8 to
day 35 (1ml of concentrated oil derived from
Amaranthus cruenthus seeds by the method of CO2
extraction, AO was provided by NVF “Danika”, Kharkiv,
Ukraine). Oil was taken orally once daily at least 30min
before breakfast. Patients were provided with sufficient
amount of oil and were instructed how to take it. All
patients recruited in the study assigned to group 2
reported no compliance failures (failing to take at least
six doses of AO in 6 days per respective week in appro-
priate time).
Control group consisted of 40 gender and age-
matched healthy subjects without any clinically mani-
fested health disorders or complaints related to gastro-
intestinal or cardiovascular diseases. These subjects
underwent upper gastrointestinal endoscopy with
acquisition of gastric mucosa samples once at the begin-
ning of the study. Patients with H. pylori-negative DPU
were excluded from the main part of the study after con-
firmation of absence of the microorganism. Neither H.
pylori-negative patients nor control group subjects were
prescribed anti-Helicobacter treatment or AO. All
recruited patients and apparently healthy subjects par-
ticipated in the study voluntarily, were aware of required
procedures and potential risks. Informed consent was
obtained in all screened subjects. The protocol of the
study was approved by institutional ethics committee of
Danylo Halytskyi Lviv National Medical University before
the beginning of any of the procedures of the study.
Histology, immunohistochemistry, and
determination of H. pylori
For histological examination two biopsy specimens
were obtained endoscopically from antrum and two
from corpus of the stomach in all DPU patients as it is
known that H. pylori lives predominantly in these gastric
parts. As this microorganism is rarely observed in the
duodenum, no samples from this region were obtained
while the risk of complications (perforation, haemor-
rhage) is much higher. The biopsy specimens were
immediately fixed in buffered 10% formalin, then dehy-
drated in ethanol and embedded in paraffin, cut into
5-mm thick sections and examined with haematoxylin-
eosin and modified Giemsa staining. Histologically,
H. pylori infection was considered as negative if H. pylori
was absent in all biopsies obtained from one patient
and positive if it was in at least one sample.
Additionally, one antral biopsy specimen was taken for
rapid urease test. Inflammation, presence of H. pylori,
glandular atrophy, and intestinal metaplasia were classi-
fied qualitatively as negative (0) or positive (1); and
semiquantitatively into four grades according to
updated Sydney System as follows: 0, none; 1, mild; 2,
moderate, and 3, severe. Representative paraffin blocks
obtained only from patients with successful eradication
of H. pylori before and after treatment were further
used for immunohistochemical staining: one slice of
each specimen was cut into 5-mm thin sections,
mounted on a slide coated with (3-aminopropyl) trie-
thoxysilane, deparaffinated in xylene, and rehydrated
through a series of ethanol.
Immunohistochemistry for HNE-modified proteins
was carried out as described before [15,16] using mono-
clonal antibodies obtained from culture medium of
clone “HNE 1g4” produced by the fusion of Sp2-Ag8
myeloma cells with B-cells of a BALB-c mouse immu-
nised with HNE-modified keyhole limpet haemocyanin
[34]. The antibody is specific for the HNE-histidine epi-
tope in HNE–protein (peptide) conjugates and gives
only 5% cross-reactivity with HNE-lysine and 4% with
HNE-cysteine. Immunohistochemistry was done in a
three-step procedure as described before using LSAB kit
(DAKO, Denmark) where the first step was incubation
with anti-HNE-histidine monoclonal antibodies (dilution
1:10) for 2 hrs in humid chambers at room temperature.
The second step was incubation with biotinylated sec-
ondary goat antimouse and antirabbit immunoglobulins
(AB2) for 30min. The third step was incubation with
streptavidin-peroxidase for 30min. Finally, the reaction
was visualised with DAB (3.3-diaminobenzidine tetrahy-
drochloride in organic solvent; DAKO, Denmark) after
10min of incubation. Negative control was done on one
histological slice of the same tissue, without application
of the HNE-histidine specific monoclonal antibodies. The
intensity and distribution of the HNE-immunostaining in
the gastric mucosa from antrum and corpus of the stom-
ach were evaluated semiquantitatively. The absence of
immunopositivity in the cytoplasm and nuclei of glandu-
lar epithelial cells was marked with (0), while with (1) we
marked weak immunopositivity in less than 25% of the
cells, with (2) medium immunopositivity in 25–50% of
cells and, finally, with (3) strong immunopositivity in
more than 50% of cells. In superficial and foveolar epi-
thelium as well as in lamina propria of the gastric
mucosa we distinguished only positive (1) and negative
(0) immunostaining. All immunohistochemical analyses
were done by a pathologist experienced in the HNE
immunohistochemistry without prior knowledge of the
study group design.
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Heart rate variability
Briefly, during quiet wakefulness in the morning hours,
not less than 24 hours after the last significant physical
exercise, the short-time records of ECG were performed.
A computer electrocardiograph “VNS-Micro” (NeurosoftVR ,
Ivanovo, Russia) was used for ECG records. After 20min
of rest, studied subjects were asked to stay supine
quietly for 5.0min to ensure quasi-stationary condition
HRV recording; afterwards they were asked to stand up
rapidly and remained in the standing position for 6min
– active orthostatic test (OT). RR intervals were deter-
mined with a sampling frequency of 2.0 kHz and were
analysed with “Poly-Spectrum” (NeurosoftVR , Ivanovo,
Russia) software designed according to HRV standards 7.
The time-domain parameters – standard deviation of
normal RR intervals (SDNN), the square root of the mean
squared differences of successive RR intervals (RMSSD),
and percentage of differences between adjacent normal
RR intervals exceeding 50 milliseconds (pNN50) were
determined. The power spectral analysis was performed
sequentially with a fast Fourier transformation. The fol-
lowing frequency-domain variables were studied: total
power (TP, 0.01–0.40 Hz), high frequency power (high
frequency (HF), 0.15–0.40Hz), low frequency power (low
frequency (LF), 0.04–0.15Hz), and very low frequency
power (very low frequency (VLF), 0.01–0.04Hz). For more
details about the procedure and method of short period
HRV recording please refer the reference [35].
Statistical analysis
All data were processed using the statistical package
IBM SPSS Statistics 24 (Armonk, NY). Normal distribution
of the obtained data was confirmed with Shapiro–Wilk’s
W-test. Normally distributed data was presented as
means ± standard error mean (M±m) and abnormally
distributed parameters (most of the parameters of HRV)
as median (quartile range). The descriptive data defined
a positive/negative is presented as number of positive
and % of total. Nonparametric Mann–Whitney U-test
was used to compare HRV parameters and semi-quanti-
tative data, chi-square test was used for qualitative data
presented as positive/negative. In figures, data are pre-
sented as mean and standard error mean (error bar). If
not indicated otherwise, p< .05 was considered as
significant.
Results
Clinical symptoms and endoscopy
The most common symptom of DPU is epigastric pain,
which was observed in 35 (89.7%) and 34 (94.4%)
patients in groups 1 and 2, respectively. Less frequent
symptoms include pyrosis, eructation with acid, vomit-
ing, flatulence, constipation, and diarrhoea (Table 1).
Treatment provided radical improvement of patients’
condition and in most patients all the symptoms disap-
peared (Table 1) or were observed only occasionally.
We did not observe significant differences between
group 1 and group 2 after treatment (p> .05, Table 1).
Similarly, the frequency of symptoms detected during
physical examination (coated tongue, halitosis, and
painful epigastric palpation) significantly decreased
after treatment, while indicated differences between
the groups were not significant (Table 1). Along with
ulcers (present in 100% of patients included in groups 1
and 2) an endoscopic evidence of gastritis and duoden-
itis was obtained for almost all patients (Table 2). Other
findings included gastroesophageal reflux, endoscopic
evidence of reflux esophagitis, duodeno-gastral reflux
and the presence of scar in the duodenum, as a result
of healing of ulcers in prior periods (Table 2). After treat-
ment, significant improvement of majority of endo-
scopic symptoms was observed and complete or almost
complete ulcer healing was reported. In case of duo-
denal reflux and scar deformation the difference before
and after treatment was not significant, as were no sig-
nificant differences between groups 1 and 2.
H. pylori and histology of GM samples
(comparison of DPU patients and control group)
Helicobacter pylori contamination in control group
(apparently healthy age- and gender-matched subjects
Table 1. The frequencies of principal clinical symptoms in H.
pylori-positive DPU patients before and after treatment, the
absolute (n) and respective relative values (%) are presented.
Symptom
Before treatment After treatment
Group 1
(n¼ 39)
Group 2
(n¼ 36)
Group 1
(n¼ 39)
Group 2
(n¼ 36)
Complaints
Pain (in epigastrium) 35 (89.7%) 34 (94.4%) 4 (10.3%)c 2 (5.6%)c
Pyrosis 12 (30.8%) 13 (36.1%) 3 (7.7%)b 1 (2.8%)c
Eructations with acid 15 (38.5%) 14 (38.9%) 1 (2.6%)c 0 (0.0)c
Nausea 17 (43.6%) 15 (41.7%) 2 (5.1%)c 1 (2.8%)c
Vomiting 7 (17.9%) 4 (11.1%) 0 (0.0%)b 0 (0.0%)a
Flatulence 10 (25.6%) 7 (19.4%) 3 (7.7%)a 2 (5.6%)
Constipations 15 (38.5%) 12 (33.3%) 4 (10.3%)b 1 (2.8%)c
Diarrhoea 3 (7.7%) 1 (2.8%) 1 (2.6%) 0 (0.0%)
Physical examination
Coated tongue 15 (38.5%) 13 (36.1%) 6 (15.4%)a 3 (8.3%)b
Halitosis 13 (33.3%) 9 (25.0%) 4 (10.3%)a 2 (5.6%)a
Painful epigastric palpation 37 (94.9%) 36 (100.0%) 1 (2.6%)c 0 (0.0%)c
aDifference between before and after treatment in respective group is
significant by v2 test p< .05.
bDifference between before and after treatment in respective group is
significant by v2 test p< .01.
cDifference between before and after treatment in respective group is
significant by v2 test p< .001.
There was no significant difference detected between group 1 and 2
neither before nor after the treatment (p> .05).
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without gastrointestinal complaints) was detected in
16 subjects (40%), while, naturally, in DPU patients con-
tamination was significantly higher (71.4%; p< .001). H.
pylori was detected in 75 patients, as shown in Table 3.
Monocytic infiltration was clearly associated with H.
pylori positivity and chronic inflammation in GM. It was
the case in almost all the subjects, both in apparently
healthy controls and in DPU patients (Table 3).
However, neutrophils were observed only in some
samples of H. pylori-positive subjects and were associ-
ated with more severe inflammation either acute or
exacerbation of the chronic inflammation (Table 3). The
results of histological examination in antrum and corpus
of stomach were generally consistent with slightly more
pronounced inflammatory changes observed in antrum
(pylorus), H. pylori’s “favourite” region (Table 3).
Lymphoid follicles were also more frequently find in
DPU patients, especially in antrum (p< .001, Table 3).
We did not observe significant difference in degree of
microbial contamination of H. pylori between appar-
ently healthy subjects and DPU patients, p> .05.
Moreover, control group showed slightly higher aggre-
gate rates of second and third degrees compared to
DPU patients, and more than 50.0% of DPU patients
had low degree of H. pylori contamination (Table 4).
This suggests that the presence of H. pylori in stomach
mucosa itself is probably more important factor than
the degree of its contamination, while the outcome of
this pathogen–host interaction depend lot on the
host’s intrinsic resistance, metabolic efficiency, and
flexibility.
H. pylori and histology of GM samples of DPU
patients before and after treatment
Treatment aimed to eradicate H. pylori lead to marked
improvement of histological pattern of GM specimens.
Efficiency of eradication according to histological evalu-
ation was found to reach 92.5 and 94.4% in groups 1
and 2, respectively, with p< .001 in both cases (Table
5). A strong reduction of inflammatory signs (accumula-
tion of neutrophils, monocytes, and lymphoid follicles)
was observed to be associated with elimination of infec-
tion, however, in some cases, especially in group 1
accumulation of leucocytes, mainly monocytes,
remained (difference between the groups after treat-
ment p< .01 in antrum and p< .05 in corpus, Table 5).
The rates of atrophy, metaplasia, and dysplasia did not
Table 2. Endoscopic changes detected in DPU patients before and after treatment, the absolute (n) and
respective relative values (%) are presented.
Finding
Before treatment After treatment
Group 1 (n¼ 39) Group 2 (n¼ 36) Group 1 (n¼ 39) Group 2 (n¼ 36)
Gastritis 37 (94.9%) 35 (97.2%) 10 (25.6%)c 8 (22.2%)c
Duodenitis 39 (100.0%) 36 (100.0%) 9 (23.1%)c 7 (19.4%)c
Gastroesophageal reflux 13 (33.3%) 13 (36.1%) 5 (12.8%)a 3 (8.3%)b
Reflux oesophagitis 7 (17.9%) 10 (27.8%) 3 (7.7%) 2 (5.6%)a
Duodenogastral reflux 17 (43.6%) 15 (41.7%) 8 (20.5%)a 8 (22.2%)
Scar deformation of duodenum 14 (35.9%) 12 (33.3%) 14 (35.9%) 12 (33.3%)
aDifference between before and after treatment in respective group is significant by v2 test p< .05.
bDifference between before and after treatment in respective group is significant by v2 test p< .01.
cDifference between before and after treatment in respective group is significant by v2 test p< .001.
There was no significant difference detected between group 1 and 2 neither before nor after the treatment.
Table 3. H. pylori contamination and the results of histological
examination of gastric mucosa in apparently healthy subjects
(control group) and DPU patients (including H. pylori-nega-
tive), the absolute (n), and respective relative values (%) are
presented.
Parameter
Control group
(n¼ 40)
DPU patients
(n¼ 105)
Difference by
v2 test, p value
Antrum
H. pylori 16 (40.0%) 75 (71.4%)c <.001
Neutrophils 4 (10.0%) 24 (22.9) .061
Monocytes 15 (37.5%) 85 (81.0%)c <.001
Atrophy 0 (0.0%) 10 (9.5%)a .043
Metaplasia 0 (0.0%) 4 (3.8%) .211
Dysplasia 0 (0.0%) 6 (5.7%) .123
Lymphoid follicles 3 (7.5%) 37 (35.2%)c <.001
Corpus of stomach
H. pylori 14 (35.0%) 67 (63.8%)b .004
Neutrophils 4 (10.0%) 15 (14.3%) .494
Monocytes 15 (37.5%) 77 (73.3%)c <.001
Atrophy 0 (0.0%) 17 (16.2%)b .007
Metaplasia 0 (0.0%) 2 (1.9%) .379
Dysplasia 0 (0.0%) 0 (0.0%) 1.000
Lymphoid follicles 3 (7.5%) 25 (23.8%)a .026
aDifference between the groups significant with p< .05.
bDifference between the groups significant with p< .01.
cDifference between the groups significant with p< .001.
Table 4. The distribution of H. pylori-positive apparently
healthy subjects and H. pylori-positive DPU patients by degree
of microbial contamination of gastric mucosa, the absolute (n)
and respective relative values (%) are presented.
Degree of H. pylori
contamination
Control group of
apparently healthy
subjects (n¼ 16)
DPU patients
(n¼ 75)a
I 8 (50.0%) 44 (58.7%)
II 5 (31.3%) 19 (25.3%)
III 3 (18.8%) 15 (20.0%)
aThe difference between the groups is insignificant according to
Mann–Whitney U test (p> .05).
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differ significantly between the groups and remained at
relatively low level (Table 5).
Accumulation of 4-hydroxynonenal-histidine
adducts in gastric mucosa
Individual variations of the appearance of the HNE-
histidine adducts were observed in both patients and
in control group, however, there was a clear evidence
that accumulation of HNE in H. pylori-positive DPU
patients was higher than in H. pylori-negative and H.
pylori-positive apparently healthy subjects in antrum
(Figure 2(A,B)) and corpus (Figure 3(A,B)). In the con-
trol group, mild and occasional accumulation of HNE
was observed in superficial and foveolar epithelium of
antrum of the stomach, while in corpus these cells
were found to be free of HNE. In lamina propria,
accumulation of HNE was observed in 35.0% cases in
antrum and 40.0% in corpus of stomach of subjects
from control group (Figures 2(C),3(C)). The HNE immu-
nopositivity in glandular epithelium was detected in
almost all studied healthy subjects and patients
Table 5. Helicobacter pylori contamination and the results of
histological examination of gastric mucosa in DPU patients
before and after treatment, the absolute (n) and respective
relative values (%) are presented.
Before treatment After treatment
Group 1 Group 2 Group 1 Group 2
Antrum
H. pylori 39 (100.0%) 36 (100.0%) 3 (7.75)c 2 (5.6%)c
Neutrophils 12 (30.8%) 13 (36.1%) 1 (2.6%)c 0 (0.0%)c
Monocytes 38 (97.4%) 36 (100.0%) 12 (30.8%)c 2 (5.6%)c,e
Atrophy 4 (10.3%) 4 (11.1%) 4 (10.3%) 1 (2.8%)
Metaplasia 2 (5.1%) 1 (2.8%) 2 (5.1%) 0 (0.0%)
Dysplasia 2 (5.1%) 2 (5.6%) 1 (2.6%) 0 (0.0%)
Lymphoid follicles 15 (38.5%) 11 (30.6%) 3 (7.7%)b 0 (0.0%)c
Corpus of the stomach
H. pylori 36 (92.3%) 32 (88.9%) 2 (5.1%)c 1 (2.8%)c
Neutrophils 12 (30.8%) 10 (27.8%) 1 (2.6%)c 0 (0.0%)c
Monocytes 37 (94.9%) 31 (86.1%) 8 (20.5%)c 1 (2.8%)c,d
Atrophy 5 (12.8%) 7 (19.4%) 4 (10.3%) 4 (11.1%)
Metaplasia 2 (5.1%) 1 (2.8%) 2 (5.1%) 0 (0.0%)
Dysplasia 0 (0.0) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Lymphoid follicles 13 (33.3%) 9 (25.0%) 3 (7.7%)c 0 (0.0%)b
bThe difference between before and after treatment significant by v2 test.
p< .01 in respective group.
cThe difference between before and after treatment significant by v2 test,
p< .001 in respective group.
dThe difference between the groups significant by v2 test, p< .05.
eThe difference between the groups significant by v2 test, p< .01.
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Figure 2. Accumulation of 4-hydroxynonenal–histidine adducts in gastric mucosa of antrum of studied subjects (qualitative evalu-
ation, expressed as % of cases with respective HNE-immunopositivity of samples). Statistical evaluation by Chi-square test (non-
significant not indicated): (A) Control vs. G1 after p< .01, Control vs. G2 after p< .0001, G1 before vs. G1 after p< .01, G1 before
vs. G2 after p< .001, G2 before vs. G1 after p< .05, G2 before vs. G2 after p< .01, G1 after vs. G2 after p,.01; (B) Control vs. G2
before p< .05, Control vs. G1 after p< .001, G1 before vs. G1 after p< .01; G1 before vs. G2 after p< .01, G2 before vs. G1 after
p< .05, G2 before vs. G2 after p< .01, G1 after vs. G2 after p< .001; (C) Control vs. G1 after p< .001, G2 before vs. G1 after
p< .01; (D) all nonsignificant; (E) Control vs. G1 before p< .01; Control vs. G2 before p< .05, Control vs. G1 after p< .001; G1
before vs. G2 after p< .01, G2 before vs. G1 after p< .05, G2 before vs. G2 after p< .05, G1 after vs. G2 after p< .001.
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before and after treatment (statistical difference not
significant, p> .1), however, the pattern of this accu-
mulation was different.
The HNE immunopositivity of cytoplasm of glandular
cells was observed almost in all subjects, while the
nuclei of granulocytes in samples obtained from control
subjects did not show accumulation of HNE–histidine
adducts. At the same time, in considerable number of
patients besides cytoplasmic accumulation, the HNE
immunopositivity in substantial number of samples the
accumulation of HNE–histidine adducts in nuclei was
also observed (Figures 2(D), 3(D)). Standard treatment
did not cause significant reduction of HNE immunoposi-
tivity of nuclei of glandular cells in antrum and in cor-
pus of the stomach (Figures 2 and 3). In contrast to the
standard treatment, AO supplementation provided sig-
nificant reduction of nuclear HNE accumulation in DPU
patients in both antrum and corpus of the stomach
(Figures 2(E) and 3(E)).
In order to study in more details the pattern of HNE
accumulation in glandular cells, we performed semi-
quantitative evaluation of HNE immunopositivity as
described in methods section (Figure 4). Despite the
evidence that HNE immunopositivity in glandular cyto-
plasm was common finding and is observed almost in
all subjects the intensity (degree) of HNE–protein accu-
mulation was different. The patients before treatment
had higher rate of grade 3 (the most severe) HNE immu-
nopositivity in cytoplasm of glandular cells compared to
controls (for statistical evaluations see figure captions).
Standard treatment did not change this pattern signifi-
cantly in antrum (Figure 4(A)), while in corpus the rate
of severe accumulation of HNE–histidine adducts fur-
ther increased (Figure 4(C)). Similar findings were
observed in nuclei of glandular cells – there was a ten-
dency of increase in grade 3 HNE immunopositivity of
nuclei in both antrum and corpus of the stomach
(Figures 4(B,D)).
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Figure 3. Accumulation of 4-hydroxynonenal–histidine adducts in gastric mucosa of corpus of stomach of studied subjects (quali-
tative evaluation, expressed as % of cases with respective HNE-immunopositivity of samples). Statistical evaluation by Chi-square
test (nonsignificant not indicated): (A) Control vs. G1 before p< .001, Control vs. G2 before p< .001, Control vs. G1 after p< .001,
Control vs. G2 after p< .001, G1 before vs. G1 after p< .01, G2 before vs. G1 after p< .01, G1 after vs. G2 after p,.001; (B) Control
vs. G1 before p< .001, Control vs. G2 before p< .001, Control vs. G1 after p< .001, Control vs. G2 after p< .01, G1 before vs. G1
after p< .01, G2 before vs. G1 after p< .01, G1 after vs. G2 after p,.001; (C) Control vs. G1 after p< .01, G1 before vs. G2 after
p< .001, G2 before vs. G1 after p< .05, G2 before vs. G2 after p< .001, G1 after vs. G2 after p< .001; (D) all nonsignificant; (E)
Control vs. G1 before p< .001; Control vs. G2 before p< 0.001, Control vs. G1 after p< .001.
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The HNE immunopositivity patterns of HNE-histidine
immunohistochemical staining are presented as follows:
before treatment (Figure 5(A,C)), after standard treat-
ment (Figure 5(B,D)) and after standard treatment with
AO supplementation (Figure 6).
HRV parameters in DPU patients before and after
treatment
Time and frequency domain parameters of HRV were
determined in all studied subjects and the results are
summarised in Tables 6 and 7. DPU patients have
increased heart rate (HR) and decreased HRV parame-
ters (Table 6). After standard treatment further decrease
in SDNN, RMSSD, and pNN50 (p< .05) was observed,
while HR did not change (p> .05, Table 6). In contrast,
mild decrease in HR was statistically significant for the
group 2 (p< .05, Table 6).
The results of determination of spectral (frequency
domain) parameters showed similar changes to time
domain indexes (Table 7). DPU patients of both groups
before treatment had significantly lower TP, VLF, LF,
and HF, with higher LF/HF ratio in comparison to con-
trol group (Mann–Whitney U-test, p< .05). Likewise,
after standard treatment further reduction of TP, VLF,
LF, and HF was observed (p< .05, Table 7). Patients of
group 2, who were supplemented with AO, showed
increase in most of spectral parameters of HRV, how-
ever, only for HF (indicating parasympathetic activity)
statistical significance was obtained (p< .05, Table 7).
Notably, all spectral parameters of HRV in group 2 after
treatment were significantly higher than respective
parameters of group 1 (p< .05), and in cases of VLF and
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Figure 4. Semiquantitative evaluation of the accumulation of 4-hydroxynonenal–histidine adducts in cytoplasm and nuclei of
glandular cells of gastric mucosa of antrum and corpus. Nonparametric Mann–Whitney U test was used to compare the pattern
of HNE-immunopositivity in studied patients (nonsignificant differences not indicated): (A) Control vs. G2 before p< .05, others
p> .05; (B) Control vs. G1 before p¼ .05, Control vs. G1 after p< .01, G2 before vs. G1 after p< .05, G1 after vs. G2 after p< .01;
(C) Control vs. G1 before p< .01, Control vs. G2 before p< .001, Control vs. G1 after p< .001, Control vs. G2 after p< .001, G1
before vs. G1 after p< .001, G1 before vs. G2 after p< .05, G2 before vs. G1 after p< .01; (D) Control vs. G1 before p< .01,
Control vs. G2 before p< .05, Control vs. G1 after p< .01.
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HF reached or slightly exceeded the values of healthy
subjects (Table 7). The effects of AO on HRV (improve-
ment of parameters reflecting parasympathetic tone)
were this consistent with the effects on HNE–histidine
adducts accumulation in GM (reduction of HNE immu-
nopositivity in group with AO supplementation in add-
ition to standard treatment).
Discussion
The results of this study confirm the capabilities of sup-
plementation of AO to modulate redox balance and
reduce manifestations of OS in GM of patients with H.
pylori-associated DPU in clinical conditions. It was dem-
onstrated that elevated levels of HNE–histidine adducts
in GM observed in acute stage of DPU in most of the
patients remain after treatment at the high levels des-
pite the evidence of clinical improvement (decrease or
complete disappearance of clinical symptoms, effective
ulcer healing, normalisation of GM histology, and eradi-
cation of H. pylori), but AO supplementation additional
to standard treatment, hence not influencing signifi-
cantly clinical outcomes of DPU, causes reduction of OS
manifestation within the study time frame. In addition
to local effects in GM, a systemic effect in the form of
HRV improvement was observed.
Helicobacter pylori is well-known pathogen colonising
GM of billions of people worldwide and often causing
chronic gastritis, peptic ulcers, gastric cancer, and a
number of other health problems [36]. Ability to induce
OS in stomach is well documented pathogenic property
of this bacterium, and a growing body of evidence sug-
gest that this effect may be systemic causing numerous
extragastric manifestations of H. pylori [9,37–39]. Altered
redox signalling plays a central role as a cause and con-
sequence of acute and chronic inflammation, gastric
carcinogenesis, dysregulation of prostaglandin metabol-
ism, release of proinflammatory cytokines in blood-
stream and causing low-grade inflammation,
potentially contributing to the development of insulin
resistance, endothelial dysfunction, and related prob-
lems [40–42].
Figure 5. Immunohistochemical determination of HNE–histidine conjugates before and after standard treatment. Images A and B
reveal a marked accumulation of HNE-histidine adducts in cytoplasm and nuclei of majority of gastric glandular cells. Superficial
and foveolar epithelium as well as lamina propria show significant HNE immunopositivity, however, the most significant accumula-
tion is observed in glandular cells. C and D – the pattern of accumulation and distribution of HNE-histidine conjugates 4 weeks
after end of eradication treatment is comparable with the pattern before treatment and in glandular epithelium grade of HNE
immunopositivity is even greater.
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Eradication of H. pylori, however, often does not
cause instant effect and substantial time is needed to
eliminate the consequences of H. pylori contamination
as a risk factor for various disorders. For example, in
case of gastric cancer successful H. pylori eradication
significantly reduces risk of this common and often
deadly neoplasm only after 8–10 years or more [5].
Molecular milieu of such an unusual “posteradication”
persistence of OS is not completely understood and
requires further in-depth analysis.
Immunohistochemistry is well recognised, advanced
method of HNE determination in tissues and
Figure 6. Immunohistochemical determination of HNE–histidine conjugates after standard treatment with additional Amaranth oil
supplementation. A, B moderate accumulation of HNE–histidine adducts predominantly in cytoplasm of glandular cells after 4
weeks of Amaranth oil supplementation, that started just after the end of eradication treatment. Nuclear accumulation of HNE-his-
tidine adducts is not observed. The staining of superficial and foveolar epithelium and lamina propria shows absence of or low
HNE immunopositivity. C, D – higher magnification confirms the findings from images A and B. There is the evidence of the
reduction of HNE-histidine adducts accumulation in gastric mucosa compared to the condition before treatment and after stand-
ard treatment.
Table 6. Heart rate and time domain parameters of heart rate variability in DPU patients before and after treatment and appar-
ently healthy subjects, median (quartile range).
Heart rate, beats/min. SDNN, ms RMSSD, ms pNN50, %
Group 1 before treatment (n¼ 39) 76.5 (16.0)i 36.0 (23.0)i 22.0 (19.0)i 2.9 (10.3)i
Group 1 after treatment (n¼ 39) 73.1 (11.1)h 26.2 (16.1)c,i 18.5 (6.2)b,i 1.3 (2.9)a,i
Group 2 before treatment (n¼ 36) 75.9 (11.0)h 41.1 (20.8)h 29.0 (20.1)h 6.5 (14.8)h
Group 2 after treatment (n¼ 36) 70.0 (8.3)a 43.2 (5.8)h,e 33.0 (4.4)g,e 14.0 (10.9)g,e
Control group (n¼ 40) 70.0 (13.0) 50.0 (32.0) 38.0 (35.0) 18.5 (35.0)
aThe difference between before and after treatment within the groups significant, p< .05.
bThe difference between before and after treatment within the groups significant, p< 0.01.
cThe difference between before and after treatment within the groups significant, p< .001.
eThe difference between the parameters of groups after treatment significant, p< .01.
gThe difference compared to control group significant, p< .05.
hThe difference compared to control group significant, p< .01.
iThe difference compared to control group significant, p< .001.
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significantly contributed to the establishment of the
role of HNE in health and disease. It became evident by
immunohistochemical analysis that HNE–protein
adducts moderately accumulate not only in patho-
logical but also in physiological conditions being more
pronounced under onset of chronic or acute OS, both
due to exogenous stressors (toxins, microbial agents,
hypo/hyperoxia) and to the endogenous pathophysio-
logical processes such as inflammation related to car-
cinogenesis and/or defence against cancer etc. [15,16]
Hence, the HNE-immunohistochemistry allows us to
evaluate accumulation and distribution of HNE–protein
adducts, that contributes to improvement of the quality
and precision of the analysis [12].
Amaranth oil was previously demonstrated to have
redox-modulating properties and efficiency in relieving
of OS manifestation in high-level competitive athletes
[21], diabetic, coronary artery disease, and hypertension
patients [32]. Animal studies also showed substantial
therapeutic potential of AO in treatment of hyperchol-
esterolemia [43], antitumour activity [44] etc.
Considering unique chemical composition and high
content of squalene, polyunsaturated fatty acids, toco-
pherols, and tocotrienols, potential redox-modulating
activity of AO could be attributed to its metabolically
active components that, in case of gastroduodenal dis-
eases, could be directly delivered to the site when
administered orally [32].
The effects of AO in our clinical setup were consist-
ent with the previous findings from the literature
described above. In fact, standard treatment of DPU
directed on H. pylori eradication causes dramatic
improvement of clinical symptoms, healing of the
ulcers, and reducing inflammation (Tables 1, 2, and 5),
however, the evidence from HNE-immunohistochemis-
try indicates persistence of OS in GM, despite successful
H. pylori eradication (Figures 2–6). Obviously, eradica-
tion of H. pylori is a major contributor to reduction
of number of inflammatory cells in mucosa samples
(Table 5), and, to some extent, AO may also contribute
to this effect (significant reduction of monocytes in
AO-treated group compared to standard treatment,
Table 5). However, this is probably not the major effect
of AO, since the inflammation was dramatically reduced
in both groups after treatment, while reduction of
HNE–adducts accumulation was observed mainly in
group 2. Despite individual variability of the patients’
response to treatment, the AO provided significant
reduction of the HNE–histidine adducts in GM and
therefore local reduction of OS manifestations. Thus,
anti-OS effect of AO, at least in part, seems to be inde-
pendent on anti-inflammatory effect.
However, the effects of AO are not limited to local
impact on GM. It was shown that AO supplementation,
in contrast to standard treatment, improves HRV in DPU
patients after H. pylori eradication. On the other hand,
cholinergic effects of AO at systemic level, in turn, may
also contribute to anti-inflammatory effects at the level
of gastric mucosa [24,25] due to improvement of endo-
thelial function and local blood flow that is known to
have major effect on ulcer healing [45].
Since AO is a relatively complex mixture of different
lipid components, underlying mechanisms of its redox-
modulatory effects are not clearly known. There are not
many studies addressing this issue in the literature, but
there are reasons to consider AO as a mild prooxidant
factor and its effects as hormetic response of respective
tissues/organism [46]. Considering sensitivity of HRV to
metabolic conditions in the organism [19], positive
effects of AO supplementation on HRV are not surprising.
There are several important limitations in this study.
First, immunohistochemistry is considered to be highly
specific for antigen epitope (in this case HNE-histidine
adducts), but many factors such as quality of reagents,
adequate storage of samples, etc., could reduce reliabil-
ity of the specimens processed [12]. In order to address
these issues we paid particular attention to acquire,
handle and store samples according to the optimised
protocol. Histological and immunohistochemical evalua-
tions were performed by experienced pathologists,
Table 7. Frequency domain parameters of heart rate variability in DPU patients before and after treatment and apparently
healthy subjects, median (quartile range).
TP, ms2 103 VLF, ms2 103 LF, ms2 103 HF, ms2 103 LF/HF
Group 1 before treatment (n¼ 39) 1.64 (1.99)i 0.70 (0.92) 0.48 (0.47)i 0.25 (0.45)i 1.38 (1.56)h
Group 1 after treatment (n¼ 39) 0.89 (1.04)c,i 0.47 (0.26)c,i 0.28 (0.33)c,i 0.15 (0.11)c,i 1.51 (1.92)i
Group 2 before treatment (n¼ 36) 2.16 (2.09)g 0.96 (0.74) 0.64 (0.75)g 0.44 (0,73)g 2.12 (1.52)
Group 2 after treatment (n¼ 36) 2.62 (0.35)f,g 0.84 (0.11)f 0.71 (0.11)f,g 0.97 (0.13)a,f,h 1.90 (0.26)a,e,g
Control group (n¼ 40) 3.04 (2.75) 0.85 (1.29) 0.85 (0.76) 0.86 (1.15) 0.95 (1.12)
aThe difference between before and after treatment within the groups significant, p< .05.
cThe difference between before and after treatment within the groups significant, p< .001.
eThe difference between the parameters of groups after treatment significant, p< .01.
fThe difference between the parameters of groups after treatment significant, p< .001.
gThe difference compared to control group significant, p< .05.
hThe difference compared to control group significant, p< .01.
i
The difference compared to control group significant, p< .001.
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without previous knowledge of the character of the
specimens, while the same standard reagents were
used for the simultaneous processing of the specimens.
Although we did not use confocal microscopy in
current study, the term “nuclear” accumulation of HNE-
histidine adducts refers to nuclear or perinuclear
HNE-immunopositivity, which reflects higher degree of
oxidative stress, since nuclei are very well protected
against oxidative damage [47], while such accumulation
of the HNE–histidine adducts was revealed by confocal
microscopy in previous animal study to occur predomin-
antly near nuclear membrane [48]. Finally, AO is a com-
plex mixture of different lipid compounds, therefore, it is
impossible to determine directly which of them had
major beneficial effects in our study. Hence, we also
could not measure the levels of potentially active sub-
stances in blood, which might have been involved in sys-
temic effects of AO reflected by the HRV observations.
AO supplementation is not the only intervention cap-
able to reduce local and/or systemic manifestations of
OS and the mechanism could be also quite different.
For example, positive effects of interval hypoxic training
[49], intermittent fasting/caloric restriction [29], exercise
[50], antiulcer activity of highly purified calf haemodiali-
sate [45], numerous redox-active fruits [51], and vegeta-
bles [52] that may activate oxygen metabolism may
physiologically stimulate redox signalling and cause
local and systemic metabolic effects.
Conclusions
The study has shown that supplementation of
Amaranth oil in addition to standard anti-H. pylori treat-
ment significantly reduced accumulation of HNE in GM
and increased HRV in DPU patients. Improvement of
clinical, endoscopic and histological parameters, and
successful ulcer healing was observed in both groups
and no statistically significant difference was detected.
Persistence of accumulation of the HNE–histidine
adducts after standard anti-DPU treatment requires
additional therapeutic approaches aiming to follow
modern principles of integrative medicine and reduce
manifestations of chronic oxidative stress, as was
observed in our patients after beneficial use of AO.
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